iiinova — where your digital self keeps evolving

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 16/10/2026

☁️ #cloud #AI Google Cloud 🇺🇸 $GOOGL earned a 36% operating margin in Q2 2026, up from 3% in Q3 2023. AWS 🇺🇸 $AMZN earned 39%, Microsoft's Intelligent Cloud 🇺🇸 $MSFT 41%. Google Cloud's revenue grew 82%, and Q2 was the first quarter with sales of TPU systems. midgardfinance.com/research/cloud/

Line chart titled "Google Cloud is closing the margin gap": quarterly operating margin of three cloud businesses from Q3 2023 to Q2 2026, on a vertical axis from 0% to 50%. Google Cloud, green with diamond markers, rises almost every quarter from 3% to 36%. AWS, blue with circles, moves between 30% and 39% and ends at 39%. Microsoft's Intelligent Cloud, violet with squares, stays between 40% and 45% and ends at 41%, the highest of the three. Each line is labelled at its right end with its name and latest margin.

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Koyfin @koyfin.bsky.social · 16/10/2026

Large Cap US stocks are back on top after Small Caps led the way for the majority of 2026. The S&P 500 now sits ~1.5% ahead of the Russell 2000 in YTD returns. $SPY $IWM

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Lex Investor @lex-investor.bsky.social · 15/10/2026

A second-derivative visual in cloud revenue. $GOOGL $AMZN $MSFT (info h/t Midgardfinance dot com)

3101 10

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Jesse Felder @jessefelder.com · 14/10/2026

‘This slowdown has been unusually stubborn. We’ve recorded two straight months of virtually no growth in token spend. The main driver is price declines at the frontier, in addition to efficiency and quality improvements for models across intelligence levels.‘ econlab.substack.com/p/ai-index-o...

810420 104

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 13/10/2026

🏠 #housing 🇭🇺 House prices in Hungary are up 290% since 2015, before inflation, the steepest rise in the EU. In 🇵🇹 Portugal they are up 201%. 🇫🇷 France is up 26% and 🇮🇹 Italy 21%. In 🇫🇮 Finland a home costs less than in 2015. midgardfinance.com/eu-housing/

Map of the European Union titled "EU house prices, % change since 2015". The period is 2015 to Q2 2026. Each member state is shaded blue, lighter where the figure is higher. Countries outside the EU are dark grey, and so is Greece, for which no figure is published. A list beside the map names the five highest, Hungary 290, Portugal 201, Lithuania 191, Bulgaria 185, Czechia 164, and the three lowest, France 26, Italy 21, Finland −3. Most countries carry their number on the map; Belgium, Croatia, Estonia, Latvia, Luxembourg, Slovakia, Slovenia are too small to hold one and are shaded only. Every value, highest first: Hungary 290, Portugal 201, Lithuania 191, Bulgaria 185, Czechia 164, Croatia 153, Estonia 137, Slovenia 134, Latvia 133, Poland 129, Slovakia 126, Netherlands 123, Ireland 106, Spain 101, Malta 84, Romania 82, Austria 75, Luxembourg 66, Denmark 66, Cyprus 59, Germany 54, Belgium 46, Sweden 39, France 26, Italy 21, Finland −3.

031 3

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

News from Google @newsfromgoogle.bsky.social · 12/10/2026

Over the past five years, we’ve published 90 peer-reviewed research papers with 90,000+ citations on how we’re using our machine learning models to understand and address disease globally. Today, we’re sharing key updates on that research.🧵

A person with glasses sits in front of a computer screen displaying a 3D visualization of molecular structures in red and green.

2101 10

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Jesse Felder @jessefelder.com · 11/10/2026

‘TickerTrends’ latest ARR tracking places Anthropic at $76.8B in annualized revenue run-rate, a month-over-month increase of 1.8%.‘ blog.tickertrends.io/p/openai-and...

1142 14

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 05/10/2026

📊 #pharma 🇩🇰 Novo Nordisk's semaglutide loses US exclusivity in December 2031. 🇺🇸 Eli Lilly's Mounjaro holds until June 2039. 7.5 years apart, on the two molecules the whole obesity market runs on. midgardfinance.com/obesity/ $NOVO $LLY

041 4

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 05/10/2026

💉 #obesity #EASD2026 🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients. All of EASD in one post: midgardfinance.com/blog/2026/10/04/easd-2026-roundup/

Horizontal bar chart titled "Weight loss with type 2 diabetes": weight lost by adults with obesity and type 2 diabetes on the top dose of six drugs, each beside its own trial's placebo, counting all randomised patients. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 18.8% against 5.1% on placebo. Tirzepatide 15 mg (SURMOUNT-2, 72 weeks): 14.7% against 3.2% on placebo. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 13.7% against 3.4% on placebo. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 13.2% against 3.9% on placebo. Survodutide 6.0 mg (SYNCHRONIZE-2, 76 weeks): 9.8% against 3.9% on placebo. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 9.6% against 2.5% on placebo. Retatrutide and survodutide, the two trials read out at the EASD congress, are drawn in purple and the other four in grey. These are separate trials of 68 to 80 weeks, not a head-to-head comparison.

031 3

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Steve Rattner @steverattner.bsky.social · 02/10/2026

So far, A.I.'s losers are routine office jobs like data entry keyers and customer service reps. Its winners are data scientists and the trades building the data centers like construction laborers and electricians. My @nytopinion.nytimes.com Chart: www.nytimes.com/2026/10/02/o...

76520 65

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

NEJM.org @nejm.org · 01/10/2026

In a phase 3, double-blind, placebo-controlled trial involving adults with obesity and type 2 diabetes, the investigational glucagon receptor–GLP-1 receptor dual agonist survodutide led to significant weight reduction. Full SYNCHRONIZE-2 trial results: nej.md/4yrHEMu #EASD2026

A bar chart showing the percent change in body weight from baseline to week 76, derived from an analysis-of-covariance model, for the treatment-regimen estimand, which incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and the effects of a prolonged dose-escalation period.

094 9

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 01/10/2026

💉 #pharma #EASD2026 Weight loss in type 2 diabetes, top doses, all randomised: 🇺🇸 $LLY retatrutide -18.8%, tirzepatide -14.7%; 🇩🇰 $NOVO CagriSema -13.7%, semaglutide 7.2 mg -13.2%; oral orforglipron -9.6%. Separate trials, 68-80 wk. No EloraTZP: on-drug data only. midgardfinance.com/diabetes/

Horizontal bar chart titled "Weight loss with type 2 diabetes". For each obesity drug's dedicated trial in adults with overweight or obesity and type 2 diabetes, the top dose (purple) beside that trial's placebo (grey), counting all randomised patients including those who stopped. Retatrutide 12 mg, TRIUMPH-2, 80 weeks: 18.8% vs placebo 5.1%. Tirzepatide 15 mg, SURMOUNT-2, 72 weeks: 14.7% vs 3.2%. CagriSema 2.4/2.4 mg, REDEFINE 2, 68 weeks: 13.7% vs 3.4%. Semaglutide 7.2 mg, STEP UP T2D, 72 weeks: 13.2% vs 3.9%. Semaglutide 2.4 mg, same trial: 10.4% vs 3.9%. Orforglipron 36 mg, ATTAIN-2, 72 weeks: 9.6% vs 2.5%.

041 4

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 30/09/2026

💉 #pharma #EASD2026 🇺🇸 $LLY adds amylin to tirzepatide in obesity with type 2 diabetes: -23.3% weight and -2.9 points of HbA1c at 48 weeks, vs -14.8% and -2.4 on tirzepatide alone. Stopped treatment: 11-27% on the combos, 17% on placebo, 3% on tirzepatide alone.

Two bar charts side by side titled "Amylin on top of tirzepatide, week 48", from Lilly's phase 2b trial in adults with obesity or overweight and type 2 diabetes. Six bars in each: placebo, tirzepatide 15 mg alone, and four combinations of eloralintide with tirzepatide. Left, weight loss: placebo 3.0%, tirzepatide 15 mg 14.8%, eloralintide 3 mg with tirzepatide 5 mg 13.2%, 6 with 5 19.4%, 6 with 10 19.9%, 9 with 15 23.3%. Right, HbA1c fall in percentage points: placebo 0.3, tirzepatide 2.4, then 2.2, 2.7, 2.6 and 2.9 for the combinations. All efficacy estimand.

021 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

The Lancet Diabetes & Endocrinology @thelancetendo.bsky.social · 30/09/2026

New—Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial thelancet.com/journals/lan... #obesity #EASD2026 #MedSky #EndoSky

(A) Estimated mean change in bodyweight by treatment week (efficacy estimand). (B) Least squares mean change in bodyweight from baseline to week 42 (efficacy estimand). (C) Observed mean change in bodyweight by treatment week (treatment policy estimand). (D) Least squares mean change in bodyweight (%) from baseline to week 42 (treatment policy estimand). *p<0·0001 for difference versus placebo. †Treatment policy estimates at week 42.

172 7

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 30/09/2026

💉 #obesity #EASD2026 🇺🇸 Lilly's #retatrutide 12 mg, 80 weeks, two Phase 3 trials published this week: Without diabetes (TRIUMPH-1, NEJM): -28.3% With type 2 diabetes (TRIUMPH-2, Lancet): -20.8% Same drug, same dose. Type 2 diabetes costs about a quarter of the weight loss. $LLY

Line chart of average weight change over 80 weeks on retatrutide 12 mg in two phase 3 trials published on 29 September 2026. The line that falls further is TRIUMPH-1 (New England Journal of Medicine), adults with obesity and no diabetes; the shallower line is TRIUMPH-2 (The Lancet), adults with obesity and type 2 diabetes. Both lines fall steeply for the first 36 weeks and flatten after week 52. The lines show the published average of patients on treatment, ending at -27.6 and -21.3 per cent at week 80. The two dots to the right are each trial's estimate for patients who stayed on the drug: -28.3 per cent without diabetes and -20.8 per cent with type 2 diabetes, a gap of 7.5 points. These are separate trials with different participants, so the gap is not a randomised comparison, although the drug, dose, duration and method are the same.

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

NEJM.org @nejm.org · 29/09/2026

In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz

A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

0107 10

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 29/09/2026

📊 #obesity 🇺🇸🇩🇰 Retatrutide 12 mg: 63% of patients lost a fifth of their body weight. Tirzepatide 15 mg: 63%. Semaglutide 2.4mg: 35%. Orforglipron: 20%. The average hides that. $LLY $NOVO

Grouped bar chart showing how many patients in four obesity trials reached each weight-loss level: 5, 10, 15 and 20 per cent or more of body weight. One coloured bar per drug in each group. Retatrutide 12 mg at 48 weeks, phase 2: 100 per cent reached 5 per cent, 93 per cent reached 10 per cent, 83 per cent reached 15 per cent, 63 per cent reached 20 per cent; Tirzepatide 15 mg at 72 weeks, phase 3: 96 per cent reached 5 per cent, 90 per cent reached 10 per cent, 78 per cent reached 15 per cent, 63 per cent reached 20 per cent; Semaglutide 2.4 mg at 68 weeks, phase 3: 92 per cent reached 5 per cent, 75 per cent reached 10 per cent, 55 per cent reached 15 per cent, 35 per cent reached 20 per cent; Orforglipron 36 mg at 72 weeks, phase 3: 77 per cent reached 5 per cent, 60 per cent reached 10 per cent, 40 per cent reached 15 per cent, 20 per cent reached 20 per cent. Every figure is the adherent-population estimand, which Lilly and Amgen call the efficacy estimand and Novo Nordisk the trial-product estimand, so all four bars answer the same question; the treatment-policy figures, which include patients who stopped, are lower and are not mixed in. Trial lengths differ, from 48 to 72 weeks, so this is not a controlled comparison. Retatrutide's bar is its PHASE 2 trial: its phase 3, TRIUMPH-1, reports only the 25, 30 and 35 per cent thresholds and cannot fill this ladder. The other three are phase 3. CagriSema is absent because no adherent-estimand ladder exists for it in this data, and MariTide because its 420 mg arm appears three times with three different results.

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Koyfin @koyfin.bsky.social · 27/09/2026

In 2005, Seth Klarman wrote a short paper about the painful decision to hold cash. Great read.

081 8

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 27/09/2026

💊 #pharma #MCP Our obesity and incretin trial data is now an MCP server. Ask Claude Code, get estimand-tagged answers with a citation. Free. Why it matters: the same trial reports two weight-loss numbers, up to 3.6pp apart. Twelve do. mcp.midgardfinance.com $LLY 🇺🇸 $NOVO 🇩🇰

Grouped bar chart of twelve obesity drugs, each with two bars for the same trial. The blue bar is the on-treatment (efficacy) estimand, the purple the treatment-policy estimand, both as percentage of body weight lost. Retatrutide is deepest at 28.3 against 25.0, then CagriSema 22.7 against 20.4, Zepbound 22.5 against 20.9, Wegovy HD 20.7 against 18.7, Ribupatide 19.2 against 17.7, Mazdutide 18.6 against 16.7, Bofanglutide 17.3 against 16.7, Wegovy 16.9 against 14.9, Survodutide 16.6 against 13.0, Wegovy pill 16.6 against 13.6, Ecnoglutide 14.1 against 13.2 and Foundayo 12.4 against 11.2. The on-treatment figure is higher in every case. Each pair is the top dose of that drug in the trial named, and trial durations differ, from 30 to 80 weeks, so the comparison that matters is within each pair rather than between drugs.

051 5

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

CNBC @cnbc.com · 26/09/2026

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

cnb.cx

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

163 6

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Nature @nature.com · 25/09/2026

Understanding why some people see no benefits from potent anti-obesity medications could lead to new therapies and personalized weight-loss regimens go.nature.com/3TnTlEE

go.nature.com

GLP-1 drugs fail to help some people lose weight — scientists are on a quest for answers

Understanding why some people see no benefits from potent anti-obesity medications could lead to new therapies and personalized weight-loss regimens.

1215 21

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 26/09/2026

💉 #diabetes 🇺🇸 Eli Lilly's #Onswik won FDA approval on Wednesday, the second once-weekly insulin in the US after 🇩🇰 Novo Nordisk's Awiqli in March. It lands in the flat half of Novo: insulin has sat near EUR 1.7bn a quarter since 2020, while the incretins beside it went 5.5x. $LLY $NOVO

Line chart of Novo Nordisk's revenue per quarter in euro billions, from the second quarter of 2020 to the second quarter of 2026, with two series. The incretin line, in violet, starts at about 1.5 billion, crosses the insulin line during 2021, climbs steeply through 2022 and 2023 to about 6.5 billion, peaks near 8.5 billion at the end of 2024, and ends at 8.0 billion. The insulin line, in light blue, starts at about 1.8 billion and stays between roughly 1.5 and 2.1 billion for the whole six years, ending at 1.7 billion, slightly below where it began. The two lines end far apart, with the incretins about four and a half times the insulin franchise. The title reads: Lilly's weekly insulin lands in Novo's flat half.

021 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Carl Quintanilla @carlquintanilla.bsky.social · 24/09/2026

WSJ: The AI build-out is on track to become the biggest economic bet in US history, dwarfing the investments made to fund other huge US infrastructure projects — such as the railroads, the highway system and the plumbing for the internet.” (via Jefferies)

38508183 508

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Jesse Felder @jessefelder.com · 24/09/2026

‘AI has gotten cheaper more quickly than any other transformative technology in history.’ epoch.ai/publications...

2123 12

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 22/09/2026

💉 #obesity 🇩🇰 Novo Nordisk's #CagriSema beat 🇺🇸 Eli Lilly's tirzepatide in REIMAGINE 5: 12.4% against 9.1% weight loss at 60 weeks in type 2 diabetes. At 1.0/1.0 mg, against tirzepatide's lowest 5 mg. The three head-to-heads fought at top dose all went to Lilly. $NOVO $LLY

Horizontal bar chart of the four head-to-head trials that put a Novo Nordisk incretin against an Eli Lilly one, oldest readout at the top, weight loss at the primary endpoint on a scale from zero to about 34 per cent. Each trial has two bars, the Novo arm in blue above the Lilly arm in red, and each bar is labelled with the drug, its dose and its result. Each row also says whether the arms were at their top dose. SURMOUNT-5, obesity, 72 weeks, 2025, won by Lilly, both at top dose in 2025: semaglutide 2.4 mg 13.7 per cent against tirzepatide 15 mg 20.2 per cent. REDEFINE 4, obesity, 84 weeks, February 2026, won by Lilly, both at top dose: CagriSema 2.4/2.4 mg 23.0 per cent against tirzepatide 15 mg 25.5 per cent. ACHIEVE-3, type 2 diabetes, 52 weeks, March 2026, won by Lilly, both at top dose: oral semaglutide 14 mg 5.3 per cent against orforglipron 36 mg 8.2 per cent. REIMAGINE 5, type 2 diabetes, 60 weeks, September 2026, won by Novo, neither at top dose: CagriSema 1.0/1.0 mg 12.4 per cent against tirzepatide 5 mg 9.1 per cent, the only row where the blue bar is longer than the red one.

042 4

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Our World in Data @ourworldindata.org · 16/09/2026

How fast is the world building up solar power? The International Renewable Energy Agency (IRENA) is an intergovernmental organization with 172 countries and the European Union.

46531 65

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 16/09/2026

🏭 #pharma Novo Nordisk's capex has rolled over: DKK84.1bn on a trailing twelve months, down from DKK90.1bn. Buybacks turned at the same time, DKK2.8bn to DKK5.9bn. Dividends flat at DKK52.0bn. midgardfinance.com/companies/NOVO-B.CO/ 🇩🇰 $NOVO

Line chart on a dark background titled Novo Nordisk capital allocation, trailing twelve months. Three lines in DKK billion, each a rolling four-quarter sum, running from 2021Q2 to 2026Q2, with only the final point marked and labelled at the right-hand edge.

Capex, in blue, is the top line. It falls to DKK22.4bn early in the series, climbs to a peak of DKK90.1bn at 2025Q4, and has eased for 2 quarters since to DKK84.1bn.

Dividends, in green, sit in the middle and are flat at the end: DKK52.0bn, having been near DKK52.1bn for the last four quarters.

Buybacks, in purple, are the bottom line at the end. They peak at DKK29.9bn at 2023Q4, fall to DKK2.8bn at 2025Q4, and have recovered to DKK5.9bn. Capex crosses above buybacks during 2023 and the two have not crossed back.

A trailing twelve-month basis is used because Novo pays dividends in one or two lumps a year, so a quarterly line would swing between zero and a spike. Footer text reads midgardfinance.com.

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 15/09/2026

📊 #software #stocks 🇺🇸 Adobe $ADBE trades at 10.6x free cash flow, down from 59x in 2020. In June it hit 7.8x, below its 2011 low of 10.1x. Cash per share is up 6x since 2016. midgardfinance.com/companies/ADBE/

Line chart of Adobe's share price divided by its trailing twelve-month free cash flow per diluted share, every trading day from July 2010 to today, the free cash flow stepping on the day each quarterly or annual report was filed. It stood at 10.1x in August 2011, peaked at 59x in September 2020, and after a long decline reached a low of 7.8x in June 2026, the lowest on the chart. Today, at a share price of 263 dollars against free cash flow for the twelve months to May 2026, it is 10.6x, marked in blue with a dashed line across the chart. Free cash flow per share is 6.3 times its fiscal 2016 level. Subtracting stock-based compensation, today's multiple is 13.2x.

011 1

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Peter Garnry, CFA @petergarnry.gesdacapital.com · 10/09/2026

Oracle earnings 🍿 my takeaways: Oracle NOPAT for the quarter is around 6.2bn with CapEx at 28.5bn leading to negative FCF of just ~22bn in a single quarter. CapEx increased to 28.5bn from 8.5bn a year ago.

251 5

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Koyfin @koyfin.bsky.social · 08/09/2026

The average price of electricity per Kilowatt-hour in the United States.

084 8

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

DataTrek's Nick Colas & Jessica Rabe @datatrekresearch.bsky.social · 03/09/2026

From the November 2022 launch of ChatGPT through May 2025, job postings for software developers fell by 57%. Since that trough, postings have increased by 22% even in the face of agentic coding adoption. That is a hopeful sign for other potentially AI-disrupted workers.

041 4

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Carl Quintanilla @carlquintanilla.bsky.social · 02/09/2026

RAMP: “.. the latest threat to the AI trade. AI companies' revenues are heavily dependent on a small set of customers. 80% of OpenAI and Anthropic's enterprise revenues come from 1% of their customers, and it's not getting better.” @ramp.com ramp.com/data/ai-index

2026277 262

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Carl Quintanilla @carlquintanilla.bsky.social · 01/09/2026

MIZUHO DESK: “.. Momentum baskets have now completely round-tripped and broken below their July lows, taking out the levels seen during the Situational Awareness unwind. .. The move has become increasingly self-fulfilling as systematic strategies de-risk, forcing additional selling into weakness.”

714742 147

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 31/08/2026

💉 #obesity Roche's #enicepatide lost 22.7% of body weight, edging #Zepbound's 22.5%, for a higher dropout: 7.0% against 6.2%. Its amylin #petrelintide trades half the weight loss for a 4.5% dropout. midgardfinance.com/blog/2026/08/16/obesity-challengers-second-wave-q2-2026/ 🇨🇭 $RO 🇩🇰 $ZEAL

Scatter chart of 17 obesity drugs, weight lost against the share of participants who stopped treatment for adverse events. The horizontal axis is discontinuation, the vertical axis is percentage weight lost; each dot is one asset at its top dose. The 4 challengers are picked out in colour and named with their ticker, the rest of the field is grey. Retatrutide 28.3 per cent weight loss on 11.3 per cent discontinuation; CagriSema 22.7 per cent weight loss on 5.9 per cent discontinuation; Enicepatide 22.7 per cent weight loss on 7.0 per cent discontinuation; Zepbound 22.5 per cent weight loss on 6.2 per cent discontinuation; Wegovy HD 20.7 per cent weight loss on 5.4 per cent discontinuation; Eloralintide 20.1 per cent weight loss on 7.4 per cent discontinuation; UBT251 18.7 per cent weight loss on 4.0 per cent discontinuation; Mazdutide 18.6 per cent weight loss on 2.9 per cent discontinuation; Bofanglutide 17.3 per cent weight loss on 9.4 per cent discontinuation; Wegovy 16.9 per cent weight loss on 7.0 per cent discontinuation; Survodutide 16.6 per cent weight loss on 24.8 per cent discontinuation; Wegovy pill 16.6 per cent weight loss on 6.9 per cent discontinuation; Foundayo 12.4 per cent weight loss on 8.0 per cent discontinuation; Aleniglipron 12.1 per cent weight loss on 10.4 per cent discontinuation; Cagrilintide 11.8 per cent weight loss on 4.0 per cent discontinuation; Elecoglipron 11.8 per cent weight loss on 4.1 per cent discontinuation; Petrelintide 10.7 per cent weight loss on 4.5 per cent discontinuation. These are separate trials at different doses and durations, not head-to-head comparisons. MariTide, Berobenatide, Zenagamtide, VK2735, Ecnoglutide are left off the chart because their discontinuation rates are not dose-comparable with the rest.

021 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 28/08/2026

💉 #obesity #Wegovy, #Zepbound and 4 more are being tested on heart and kidney outcomes in 79,868 patients. Only 28% sit in trials that have reported. The rest lands between 2027 and 2031. midgardfinance.com/obesity/ 🇩🇰 $NOVO 🇺🇸 $LLY $AMGN #ESCCongress

Horizontal bar chart of 10 Phase 3 trials testing obesity and diabetes drugs on heart and kidney outcomes, one bar per trial, ordered by when the trial reports. Bar length is the number of patients randomised. Grey bars are the 4 trials that have already read out, blue the 6 still running, and each bar is labelled with its year at the right-hand end. Semaglutide STEP-HFpEF, 529 patients, read out 2023; Semaglutide SELECT, 17,604 patients, read out 2023; Semaglutide FLOW, 3,533 patients, read out 2024; Tirzepatide heart failure, 731 patients, read out 2024; CagriSema REDEFINE 3, 7,101 patients, expected 2027; Tirzepatide SURMOUNT-MMO, 15,374 patients, expected 2027; MariTide MARITIME-CV, 12,800 patients, expected 2028; MariTide MARITIME-HF, 5,056 patients, expected 2028; Retatrutide cardiovascular, 10,000 patients, expected 2029; Orforglipron cardiovascular, 7,140 patients, expected 2031. In total 79,868 patients have been randomised, of whom 22,397, 28 per cent, are in trials that have reported. The largest single trial is Semaglutide SELECT at 17,604. Trials with no registry acronym are labelled by the endpoint they measure instead.

032 3

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Bloomberg News @bloomberg.com · 28/08/2026

Drugmakers were expecting big things when generic Ozempic hit Indian pharmacies. It didn’t happen.

bloom.bg

India Is One of the World’s Most Obese Countries, But Few Indians Want GLP-1s

The country shows that cost isn’t the only barrier to GLP1 drugs.

0112 11

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 24/08/2026

🇺🇸 The median S&P 500 CEO has held the job 5.1 years. Jensen Huang has run Nvidia for 34, since 1993. Only 21 of 461 have lasted twenty. Buffett dwarfed them all: 60 years at Berkshire, until January. midgardfinance.com/ceo-changes/ $NVDA $BRK.B #investing

Histogram of how long the sitting chief executive has been in post at each of 461 S&P 500 companies. The horizontal axis is years in the job in one-year bins from 0 to 40; the vertical axis counts companies. The distribution is heavily weighted to the first decade, with a dashed line at the median of 5.1 years, and thins to a long tail: 21 chief executives have been in the job twenty years or more. The longest is CoStar at 39.6 years, since 1987; the chart labels Nvidia at 34 years instead, as the recognisable one. Others past twenty include Aflac, Camden, Axon Enterprise Inc., Capital One, Gallagher, Monolithic Power. 19 companies are excluded, either because the filing record cannot show when the tenure began or because its last sighting is too old to treat the person as still in post. Companies are named, not people.

021 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 21/08/2026

🇺🇸 Moderna and Merck's cancer vaccine cleared Phase 3 in melanoma this week, and there is no pathogen anywhere in it. It teaches T cells to recognise up to 34 mutations found only in that patient's own tumour. One batch treats one person. $MRNA $MRK

Flow diagram in six numbered boxes, three across and two down, each with a small line icon, titled "Teaching T cells a target", explaining how an individualised neoantigen cancer therapy works inside the body. One, Inject, syringe icon: an mRNA shot coding for up to 34 mutations from that tumour. Two, Read, cell icon: immune cells take it up and make those mutant proteins. Three, Display, flag icon: in a lymph node they show fragments on their surface, like flags. Four, Train, dividing-cells icon: nothing taught T cells to ignore these flags, so those that fit multiply. Five, Hunt, target icon: only the tumour carries the mutations, so it alone keeps the flag flying. Six, Unblock, open-padlock icon: Keytruda stops the tumour switching those T cells off.

Flow diagram in four numbered boxes, two across and two down, each with a small line icon, titled "One patient, one vaccine", explaining how an individualised neoantigen cancer therapy is manufactured. One, Resect, DNA helix icon: the tumour comes out and is sequenced against the patient's own healthy DNA. Two, Select, funnel icon: up to 34 mutations found only in that tumour, matched to the patient's immune type. Three, Build, vial icon: all 34 encoded on one mRNA strand, wrapped in a nanoparticle, taking six to eight weeks. Four, Dose, calendar icon with nine dots: one batch, one patient, nobody else can use it, and nine doses follow, one every three weeks.

031 3

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

midgardfinance.com @midgardfinance.com · 20/08/2026

Free cash flow, TTM to Q2 2026. Building AI capacity: $ORCL -$24bn · $AMZN -$12bn · TSMC $33bn $META $41bn · $GOOGL $53bn · $MSFT $67bn Not building: $TSLA $6bn · $NVDA $119bn · $AAPL $137bn Operating cash flow rose at all nine. Capex took it.

Eight small charts, one per company, each showing operating cash flow and capital spending in billions of dollars from 2006 to the twelve months ending Q2 2026, on a shared scale, with the gap between the two lines shaded to show free cash flow. The five building AI data centres are Amazon, Alphabet, Microsoft, Meta and Oracle: at all five the cash flow rises while the spending rises faster, so the shaded gap narrows sharply after 2023, and at Amazon and Oracle the spending line has crossed above the cash flow line and the shading has gone, leaving minus 12 and minus 24 billion dollars. Microsoft ends at 67 billion, Alphabet 53, Meta 41. Apple, Nvidia and Tesla are not building: their spending stays flat and low, and the shaded gap keeps widening, to 137, 119 and 6 billion.

021 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Jesse Felder @jessefelder.com · 18/08/2026

‘Over a rolling six-month stretch, the number of stocks trading with “negative beta” to the S&P 500 recently touched the highest level going back to 1990, according to an analysis from Evercore ISI’s Julian Emanuel.‘ www.marketwatch.com/story/the-nu...

2222 22

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Koyfin @koyfin.bsky.social · 18/08/2026

Data from the SEC shows that the proceeds from US IPOs reached $115.7 billion in Q2 2026. Since the turn of the century, only Q1 2021 surpasses it, recording a staggering $132.9 billion. Data includes SPACs.

121 2

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Jesse Felder @jessefelder.com · 18/08/2026

"Apple’s premium valuation is predicated on services, and the App Store is really the crown jewel of that. We think the market is going to reprice the durability of the services business take rate [in the wake of regulatory changes]." www.ft.com/content/e553...

510727 107

Reposted by Tommy 🇪🇺🇺🇦🇬🇱

Daily Chartbook @dailychartbook.bsky.social · 18/08/2026

"The top 10% of companies using OpenAI’s products use 8.3x more tokens than the typical firm." -Exponential View

021 2